SLN-501

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameSLN-501
Drug Alias NameSLN-501
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionComplement C3 inhibitors
TargetsComplement C3
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSilence Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesSilence Therapeutics
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A